Compare HPP & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPP | ATXS |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 648.9M | 722.1M |
| IPO Year | 2010 | 2015 |
| Metric | HPP | ATXS |
|---|---|---|
| Price | $12.04 | $12.93 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 12 | 6 |
| Target Price | $19.39 | ★ $24.33 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $781,676,000.00 | $706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.69 | $3.56 |
| 52 Week High | $24.01 | $13.29 |
| Indicator | HPP | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 75.18 | 65.69 |
| Support Level | $12.91 | $12.70 |
| Resistance Level | $14.21 | $13.29 |
| Average True Range (ATR) | 0.59 | 0.22 |
| MACD | 0.42 | -0.05 |
| Stochastic Oscillator | 77.86 | 67.84 |
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.